{"entity":{"id":"nct07486687","kind":"trial","name":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","aka":["PLANET"],"tldr":"A phase 3 trial of pembrolizumab and olaparib in triple-negative breast cancer, run by The Netherlands Cancer Institute, not yet recruiting.","summary":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy is a phase 3, randomised interventional study registered as NCT07486687 by The Netherlands Cancer Institute, with a registry enrolment figure of 1000 participants, started 2026-04 and due to reach its primary completion in 2032-04. Interventions recorded: Standard of care plus pembrolizumab; Standard of care (capecitabine or olaparib). Conditions listed: Triple Negative Breast Cancer (TNBC), Early Setting; Early Stage Triple-Negative Breast Carcinoma; Triple -Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III. Triple-negative eligibility wording from the registry: \"Stage II or III TNBC prior to the start of neoadjuvant treatment\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07486687","url":"https://clinicaltrials.gov/study/NCT07486687"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor","parp-inhibitor"],"targets":[],"drugs":["pembrolizumab","olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07486687","phase":"3","setting":"PembroLizumab Adjuvant in Patients With Early-stage Triple NEgaTive Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy - the Multicenter, Randomized Phase III, Pragmatic PLANET Trial","sponsor":"The Netherlands Cancer Institute","enrolled":1000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07486687/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}